Journal: Drug Invention Today

Article Id: JPRS-P col-00004124
Title: Immune‑metabolic disorders inner endometriosis; pharmacological correction of disorders
Category: Pharmaceutics
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology

  • Abstract

    Aim: The complicacy of endometriosis pathogenesis makes it difficult to choose medical preparations for optimal effects on the main elements that determine the development and progression of this disease. The aim of the research: to study immune and metabolic disorders in female patients with internal endometriosis (adenomyosis) and to determine the effectiveness of immunomodulatory drugs and antioxidants inclusion into conventional pharmacotherapy of this disease. Method: A total of 62 female patients with verified adenomyosis Stage II confirmed by clinical and instrumental (ultrasound and hysteroscopic examination) methods were under observation. Result and discussion: Twenty female patients received only standard treatment, 21 examined ones additionally received the combinations of antioxidant and immunomodulatory drug: Ridostin and hypoxen or cycloferon and cytoflavin. All the preparations were administered according to the recommendations set forth in the Federal Manual on the Use of Drugs. In the peripheral blood, indicators of the cytokine system, complement and functional metabolic activity of neutrophils were detected. The intensity of lipid peroxidation (LPO), the state of the antioxidant system was assessed at the systemic (circulating blood plasma) and local (aspiration biopsy of the uterus cavity) levels. Conclusion: It was established that in patients with adenomyosis there is a combination of LPO activation with the development of oxidative stress with endothelial dysfunction and immune inflammation. The inclusion of drugs with immune modulating and antioxidant effects into standard pharmacotherapy corrects the development of immune inflammation, levels oxidative stress, restoring the activity of the antioxidant system enzymes and reduces the activation of LPO.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    A. Konoplya Aleksey1 , Ivanova Oksana Yurevna2 *, I. Konoplya Aleksandr3 , V. Telegina Olga2 , V. Khorlyakov Kirill 3

    Affiliation(s) Name:

    1 Department of Obstetrics and Gynecology, Faculty of Postgraduate Education, FSBEI HE Kursk State Medical University of the Ministry of Health of the Russian Federation, Kursk 305041, Russia,

    2 Department of Obstetrics and Gynecology, FSBEI HE Kursk State Medical University of the Ministry of Health of the Russian Federation, Kursk 305041, Russia,

    3 Department of Biological Chemistry, FSBEI HE Kursk State Medical University of the Ministry of Health of the Russian Federation, Kursk 305041, Russia

    *Corresponding author: Ivanova Oksana Yurevna, Department of Obstetrics and Gynecology, FSBEI HE Kursk State Medical University of the Ministry of Health of the Russian Federation, Kursk, Russia.

  • View Article File in pdf format.

    Article File

  • View Article Citation Here.

    0 View More

  • How to Cite my Article.

    Author:

    A. Konoplya Aleksey1 , Ivanova Oksana Yurevna2 *, I. Konoplya Aleksandr3 , V. Telegina Olga2 , V. Khorlyakov Kirill 3
    Title:Immune‑metabolic disorders inner endometriosis; pharmacological correction of disorders
    Journal:Drug Invention Today
    Vol(issue):11 (October )
    Year:2019
    Page No: (2407-2414)

  • Experimental Methods Keywords

    Methodology:Adenomyosis, Antioxidants, Correction, Immune metabolic disorders, Immunomodulatory drugs
    Research Materials:Immunomodulatory drugs, Twenty female patients

Keywords

Adenomyosis Antioxidants Correction Immune metabolic disorders Immunomodulatory drugs

Our Services

Register
View
Most Downloaded List

2013-2021 All rights reserved JPR SOLUTIONS